Literature DB >> 15807177

Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.

Macroui A Sonikian1, Ioanna T Pani, Anastasios N Iliopoulos, Kaliopi G Koutala, Stamatia I Marioli, Dimosthenis A Vlassopoulos.   

Abstract

Reports on acid-base side effects of sevelamer hydrochloride (SH), a new aluminum (Al)- and calcium (Ca)-free phosphate binder are rare and conflicting. In a retrospective analysis, we evaluated SH impact on metabolic acidosis and serum potassium (K) in hemodialysis (HD) patients. Two groups of stable HD patients were studied. Group A included 17 patients, M/F=15/2, 64 (42-80) years old, dialyzed since 130 (34-253) months, under SH for 24 months. Group B serving as controls was made of 7 patients, M/F=4/3, 67 (48-91) years old, dialyzed since 67 (27-174) months, under CaCO3 and/or Al(OH)3 as phosphate binders also for 24 months. Bicarbonate (BIC), K, Ca, phosphorus (P), Ca x P, alkaline phosphatase (ALP), and intact parathyroid hormone (iPTH) were recorded before (MO) and at the end (M24) of 24-month SH or CaCO3-Al(OH)3 treatment in group A and B patients. In group A, BIC fell from 20.02 +/- 1.43 to 17.89 +/- 2.30 mEq/ L, P=.002; and K rose from 5.45 +/- 0.51 to 5.75 +/- 0.49 mEq/L, P=0.02. In group B, BIC (19.8 +/- 3.03 to 19.0 +/- 3.3 mEq/L) and K (5.01 +/- 0.8 to 4.9 +/- 1.1 mEq/L) had nonsignificant changes. In group A, iPTH rose from 132.82 +/- 124.08 to 326.89 +/- 283.91 pg/mL, P=.0008; P fell from 5.92 +/- 1.48 to 4.9 +/- 1.01, P=.02; and Ca x P decreased from 52.04 +/- 9.7 to 45.58 +/- 10.42 mg2/dL2, P=.04. In group B, changes in iPTH from 240.71 +/- 174.7 to 318.57 +/- 260.2 pg/mL, P from 4.9 +/- 0.5 to 4.8 +/- 1.3 mg/dL, and CaxP product from 44.3 +/- 6.6 to 44 +/- 11.2 mg2/dL2 were nonsignificant. The changes observed in Ca and ALP in both groups were nonsignificant. Correlations in group A between metabolic acidosis (BIC) and SH doses, or iPTH and BIC, Ca, or P changes, were also found to be nonsignificant. Long-term use of SH, effectively controlling serum P levels and Ca x P values, is associated with acidosis aggravation and hyperkaliemia. Worsening of secondary hyperparathyroidism, also noted, needs to be confirmed and could be related to Ca/Al salt discontinuation and to metabolic acidosis aggravation itself.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807177

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

1.  A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Authors:  Stanley Fan; Calum Ross; Sandip Mitra; Philip Kalra; Jeremy Heaton; John Hunter; Melissa Plone; Nick Pritchard
Journal:  Nephrol Dial Transplant       Date:  2009-08-07       Impact factor: 5.992

2.  Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.

Authors:  Renske Raaijmakers; Lambertus M W Houkes; Cornelis H Schröder; Johannes L Willems; Leo A H Monnens
Journal:  Perit Dial Int       Date:  2013-05-01       Impact factor: 1.756

3.  Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-03-31

4.  Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate.

Authors:  Elizabeth Lindley; James Tattersall; Mark Wright
Journal:  NDT Plus       Date:  2008-06

5.  Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis.

Authors:  Zaw Thet; Aung Ko Win; Eugenie Pedagogos; Jennifer Beavis; Sandra Crikis; Craig Nelson
Journal:  BMC Nephrol       Date:  2013-10-01       Impact factor: 2.388

Review 6.  Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.

Authors:  Shahrzad Ossareh
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-05-08

Review 7.  Update and critical appraisal of sevelamer in the management of chronic renal failure.

Authors:  Jacob Grinfeld; Akimichi Inaba; Alastair J Hutchison
Journal:  Open Access J Urol       Date:  2010-09-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.